WuXi Biologics (Cayman) Inc. (WXXWY)

3.3300 0.0000 (0.00%) As of 10:17AM EDT. Market open.

WuXi Biologics (Cayman) Inc.

No. 108, Meiliang Road
Mashan
Wuxi 214092
China

https://www.wuxibiologics.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 12,740

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Ge Li Ph.D.	Founder & Chairman	N/A	N/A	1967
Dr. Zhisheng Chen	CEO & Executive Director	621.7k	N/A	1973
Dr. Weichang Zhou Ph.D.	Honorary President of Global Biologics Development, Senior Advisor to CEO & Non-Executive Director	417.65k	N/A	1964
Mr. Ming Tu	CFO & Executive VP	N/A	N/A	1968
Ms. Tang Shaogui M.B.A.	VP and Head of Global Communications, Operations & ESG	N/A	N/A	N/A
Dr. Sherry Gu	Chief Technology Officer and Executive VP of Global Biologics Development Department	N/A	N/A	1971
Dr. Jijie Gu	Executive VP & Chief Scientific Officer	N/A	N/A	1966
Ms. Eileen Wang	IR Senior Director	N/A	N/A	N/A
Ms. Cong Ding J.D.	VP & Head of Legal Department	N/A	N/A	N/A
He Wang	Chief Compliance Officer, Senior VP and Head of Global Compliance & Risk Management	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

WuXi Biologics (Cayman) Inc. provides end-to-end solutions and services for biologics discovery, development, and manufacturing in the People's Republic of China, North America, Europe, and internationally. It also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, and biologics clinical and manufacturing services; production and sale of medicals; vaccine contract development and manufacturing organization (CDMO) and related business; and material supplier activities. The company has a research service agreement with BioNTech SE to discover and investigate monoclonal antibodies for developing next-generation therapeutic product candidates. The company was incorporated in 2014 and is headquartered in Wuxi, China.

Corporate governance

WuXi Biologics (Cayman) Inc.’s ISS governance QualityScore as of 1 April 2024 is 9. The pillar scores are Audit: 2; Board: 10; Shareholder rights: 4; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.